An in vitro system that supports the efficient growth of hepatitis C virus (HCV) and reflects its complete in vitro replication cycle has not yet been established. The establishment of a minigene RNA of HCV in mammalian cells could facilitate the study of virus±cell interactions and the molecular pathogenesis of this virus. We constructed a replication-deficient recombinant adenovirus expressing bacteriophage T7 RNA polymerase under the control of CAG promoter (AdexCAT7). A high level of T7 RNA polymerase was detectable for at least 11 days after inoculation. Cells infected with AdexCAT7 were then transfected with plasmids carrying the authentic T7 promoter, the 5Ј untranslated region (UTR) of encephalomyocarditis virus, a luciferase gene, and a T7 terminator (pT7EMCVLuc) or carrying the modified T7 promoter, the 5ЈUTR of HCV, a luciferase gene, the coding region of C-terminal of NS5B and the 3ЈUTR of HCV, a ribozyme of hepatitis D virus and a T7 terminator (pT7HCVLuc). Most of the cell lines examined supported a higher expression of luciferase by transfection with pT7EMCVLuc than with pT7HCVLuc. However, one cell line, FLC4, derived from a human hepatocellular carcinoma, exhibited very high reporter gene expression with pT7HCVLuc. In this cell line, transfection with RNA synthesized in vitro from pT7HCVLuc induced a higher level of reporter gene expression than RNA from pT7EMCVLuc. The T7-adenovirus system for the synthesis of HCV minigenes in vivo provides useful information on the molecular mechanisms of HCV translation in human liver cells.
INTRODUCTION
Hepatitis C virus (HCV) is a major causative agent of posttransfusion and sporadic non-A, non-B hepatitis. HCV has a high propensity to cause chronic hepatitis, which may progress to liver cirrhosis and to hepatocellular carcinoma (Saito et al., 1990) . HCV is distantly related to pestiviruses and flaviviruses, and its genome consists of approximately 9400 nucleotides (nt) of positive-strand RNA encoding a single polyprotein of 3010± 3033 amino acids (Kato et al., 1990; Choo et al., 1991; Takamizawa et al., 1991) .
The genomic structure of HCV, including both the 5Ј and 3Ј termini, has been well characterized. The mechanisms of processing of the HCV polyprotein have been investigated by analyses of cDNA expression in vivo and in vitro under the control of foreign promoters using different vectors (Trono et al., 1988; Hijikata et al., 1991; Matsuura et al., 1992; Grakoui et al., 1993) . However, authentic HCV protein may not be identical to these recombinant cDNA-derived HCV proteins.
Although some lymphocyte cell lines have been shown to support partial replication of HCV (Shimizu et al., 1992; Kato et al., 1995) , there are currently no efficient in vitro systems yet to grow HCV. Recently it was reported that a full-length HCV RNA transcribed from a cDNA clone of HCV was infectious for a chimpanzee by direct injection into his liver (Kolyhalov et al., 1997; Yanagi et al., 1997) . However, propagation of the infectious RNA in cell culture has not been reported so far.
Recombinant vaccinia virus expressing bacteriophage T7 RNA polymerase (VacT7) has been used for studies on processing of HCV polyproteins (Grakoui et al., 1993; Selby et al., 1993) . This system was further applied for recovering infectious viruses from their full-size cDNA clones of negative-strand RNA viruses like, rabies virus, vesicular stomatitis virus, respiratory syncytial virus, Sendai virus, and bunyavirus (Trono et al., 1988; Conzelmann and Schnell, 1994; Collins et al., 1995; Garcin et al., 1995; Lawson et al., 1995; Bridgen and Elliott, 1996; Kato et al., 1996) . However, extensive cytopathic effects (CPE) caused by replication of a vaccinia virus vector sometimes interfere with a long-term analysis of the expressed products (Wyatt et al., 1995) and impede infectious virus recovery from their cDNAs.
The object of this study was to establish a system to facilitate the analysis of the mechanism of HCV replication in vivo. To this goal, a replication-deficient recombinant adenovirus expressing T7 RNA polymerase under the control of the CAG promoter (AdexCAT7) was made. It circumvents the CPE caused by replication of the vector virus. To establish a system to examine the translation efficiency of HCV minigene RNA in vivo, a plasmid harboring a luciferase gene flanked by 5Ј and 3Ј untranslated regions (UTR) of HCV under the T7 promoter was also made. Following transfection of AdexCAT7-infected cells with the plasmid, the HCV minigene RNA carrying the 5Ј and 3ЈUTR of HCV at both ends of the luciferase gene was efficiently synthesized in vivo. We examined various mammalian cells for luciferase expression from the minigene and found that one human hepatoma cell line supported efficient expression of HCV minigene RNA. The HCV minigene system using this cell line is useful to study the virus-cell interaction of HCV infection and other viruses for which there are no efficient in vitro replication systems.
RESULTS

Construction of AdexCAT7
AdexCAT7 was constructed by cotransfecting 293 cells with the pAdexCAT7 and EcoT22l-digested DNAterminal protein complex of adenovirus type 5 genome through homologous recombination (Fig. 1) . Purified AdexCAT7 and a control virus AxCAwt were obtained at titers of 3 ϫ 10 9 and 4 ϫ 10 10 plaque-forming units/ml, respectively.
Expression of T7 RNA polymerase in various mammalian cells infected with AdexCAT7
Various mammalian cells were infected with AdexCAT7. Cell lysates were examined for the polymerase activity by the incorporation of [ 3 H]UTP using a DNA template containing a T7 promoter and the luciferase gene (pT7Luc, Fig. 3) (Fig. 2A) . A high level of RNA polymerase activity was demonstrated in all of the cell lines examined. Polymerase activity increased with the increase in m.o.i. The cells infected with AdexCAT7 at an m.o.i. of 100 showed CPE, therefore m.o.i. 20 was employed throughout the experiments. Mammalian cells infected with AdexCAT7 were harvested periodically and examined for their T7 polymerase expression. Western blot analysis revealed continuous T7 polymerase expression for at least 11 days postinfection in HepG2 and HeLa cells (Fig. 2B) . Cells did not show any evidence of cytotoxicity during this period. Similar results were also obtained in other cell lines (data not shown). No polymerase activity was detected in cells infected with a control virus containing only the promoter sequence (AxCAwt).
Transcription of RNA from reporter plasmids
We constructed three reporter plasmids for in vivo RNA synthesis (Fig. 3) . The pT7HCVLuc plasmid possesses a modified T7 promoter and transcription was expected to start at the last G residue of the 3Ј end of the promoter. Therefore, RNA synthesized from the plasmid should have an identical sequence with that of the 5ЈUTR of HCV. pT7Luc has the luciferase gene directly under the control of the authentic T7 promoter. pT7EMCVLuc carries the 5ЈUTR sequence of encephalomyocarditis virus (EMCV) preceding the luciferase gene, which is expressed under the control of the authentic T7 promoter. In pT7EMCVLuc and pT7Luc, transcription should start efficiently from the third nucleotide upstream of the 3Ј end of the authentic T7 promoter (Fig. 3, bottom line) . Therefore, both of the transcripts should have three extra G residues at the 5Ј end. Transcriptional efficiency of pT7HCVLuc may thus be lower than that of pT7EMCVLuc and pT7Luc because of the deletion of the last two G residues from the promoter sequences (Milligan et al., 1987) .
The transcription efficiencies of these three reporter plasmids were then compared in various cells infected with AdexCAT7. Cells were harvested 6 h after transfection, and transcription levels were measured by Northern blot analysis (Fig. 4) . Efficient transcription was observed in cells transfected with pT7EMCVLuc and pT7Luc. However, in HepG2 and Huh7 cells transfected with pT7HCVLuc, no transcripts were detected. Similar results were obtained in COS7, HeLa, and CPK cells (data not shown). Only in FLC4 cells were transcripts derived from pT7HCVLuc detected, although the amounts of the transcript were smaller than those derived from pT7EMCVLuc and pT7Luc. These results suggest that the efficiency of transcription from pT7HCVLuc was enhanced in FLC4 cells.
Determination of terminal sequences of HCV minigene RNA
The above results indicated that HCV minigene RNA was transcribed well in FLC4 cells. Further experi- ments were then performed in FLC4 cells. Previous reports of the successful construction of a full-length cDNA clone of a flavivirus indicated that authenticity of the nucleotide sequences at the 5Ј end of the transcripts was crucial for recovery of the infectious virus (Rice et al., 1989; Lai et al., 1991; Sumiyoshi et al., 1992; Boyer and Haenni, 1994; Khromykh and Westaway, 1994) . Consequently, it was important to determine the precise sequence of the 5Ј terminal region of the HCV minigene RNA. A 5Ј RACE method was used to amplify the 5Ј end of the transcript, and then the 5ЈUTR sequence (position 1±207 nt) was analyzed by PCRbased direct sequencing. The 3Ј terminus structure was determined by the oligo RNA ligation method. RNA derived from pT7HCVLuc started from the expected G residue and terminated after poly (T 15 ). This structure is identical to the HCV minigene sequence in pT7HCVLuc used for transfection (data not shown).
Expression of luciferase after transfection of AdexCAT7-infected cells with the reporter plasmids Cells infected with AdexCAT7 at an m.o.i. of 20 were transfected with the reporter plasmids and examined for luciferase activity 24 h after transfection (Fig. 5) . The highest level of luciferase activity was detected in all the cells transfected with pT7EMCVLuc, whereas the lowest luciferase activity was recovered in cells transfected with pT7Luc. The luciferase activity in cells transfected with pT7HCVLuc except for FLC4 cells was 70-to 140-fold lower than pT7EMCV. However, luciferase activity in FLC4 cells transfected with pT7HCVLuc was only three times lower than that of pT7EMCVLuc-transfected cells despite the lower efficiency of transcription due to the modification of the T7 promoter (Fig. 4) . These results further suggested that translation efficiency derived from pT7HCVLuc or stability of the transcript derived from pT7HCVLuc was significantly increased in FLC4 cells.
Expression of luciferase after transfection with RNA synthesized in vitro
To examine the possibility that the efficiency of translation of RNA possessing the 5ЈUTR of HCV is higher than the EMCV-dependent translation in FLC4 cells, different cell lines were transfected with RNAs synthesized from the respective reporter plasmids in vitro and examined for luciferase activity 4±48 h after transfection (Fig. 6 ). RNA derived from pT7EMCVLuc showed a similar pattern in all three cell lines examined; the highest luciferase activity was observed 4±12 h after transfection and then gradually decreased. In HeLa and HepG2 cells transfected with RNA derived from pT7HCVLuc, results similar to those from pT7EMCVLuc were obtained. In contrast, two-to three-fold higher luciferase activity was detected in FLC4 cells transfected with RNAs derived from pT7HCVLuc than from pT7EMCVLuc. In FLC4 cells transfected with HCV minigene RNA, luciferase activity was highest 12 h after transfection and continued until at least 48 h after transfection (Fig. 6 ). These results suggested the presence of host cell factor(s) in FLC4 cells that play some role in increasing the stability of the HCV minigene RNA and/or the efficiency of translation of the RNA.
Expression of HCV core protein in FLC4 cells by the T7-adenovirus system
To determine whether HCV proteins can be synthesized in cells by the T7-adenovirus system, we constructed a plasmid, pT7HCVcore, containing the modified T7 promoter, the HCV 5ЈUTR, the HCV core gene, the coding region of C-terminal of NS5B and the HCV 3ЈUTR, rHDV and the T7ter (Fig. 3 ). FLC4 cells infected with AdexCAT7 were transfected with pT7HCVcore and examined for expression of core protein by Western blotting. The HCV core protein was detected in cell lysates prepared 1±3 days after transfection. No core protein was expressed in cells infected with the control adenovirus, AxCAwt (Fig. 7) .
DISCUSSION
In this study, we established a system to express the bacteriophage T7 RNA polymerase by using a replication-defective recombinant adenovirus. By transfection of various mammalian cells infected with AdexCAT7 with a plasmid harboring a minigene of HCV under the modified T7 promoter, one human hepatoma cell line, FLC4, was found to increase the stability and the translational efficiency of the RNA.
A vaccinia virus vector expressing T7 RNA polymerase has been used for transient viral gene expression (Fuerst et al., 1987) . This VacT7 system was particularly effective when the virus under study did not have an efficient cell-culture system for replication. The VacT7 system has contributed significantly to the understanding of the processing of HCV polyproteins (Kohara et al., 1992; Spaete et al., 1992; Grakoui et al., 1993; Selby et al., 1993; Tomei et al., 1993; Manabe et al., 1994) . Furthermore, the VacT7 system has been used in the recovery of infectious RNA viruses from their cDNA clones (Conzelmann and Schnell, 1994; Collins et al., 1995; Garcin et al., 1995; Lawson et al., 1995; Whelan et al., 1995; Kato et al., 1996) . The major benefit of this system is its broad host range, which permits foreign gene expression in many mammalian cells. However, this system is not suitable for longterm analysis of the expressed products because of its extensive CPE, and therefore it cannot be used to recover viruses like HCV whose growth is slow and inefficient. Extensive CPE caused by the vaccinia virus itself hampers the bona fide virus±cell interaction. In this context, it is noteworthy that an avian host restricted vaccinia virus, strain Ankara, has been developed which is less cytopathic for many cell types (Wyatt et al., 1995) .
Recently, Tomanin et al. reported the construction of replication competent and deficient adenoviruses possessing the T7 RNA polymerase gene under the control of the human cytomegalovirus promoter (Tomanin et al. 1997) . Although the replication-competent virus exhibited a high level of T7 polymerase expression in various cell lines, low-level expression was detected in cell lines other than 293 after infection with the replication-deficient recombinants. After coinfection with replicationdeficient adenoviruses possessing the T7 polymerase gene and the reporter gene under the control of the T7 promoter linked to the internal ribosome entry site (IRES) of EMCV, only low or no reporter activity was detected in replication-incompetent cell lines. In contrast, the T7-adenovirus constructed in our study exhibited not only a high level but long-lasting expression of T7 RNA polymerase in various mammalian cells without CPE. This might be due to the efficiency of the promoter used in the recombinant viruses. By using a ubiquitously strong promoter, it may be possible to establish a versatile expression system for various cell lines. We demonstrated here that this system is applicable to a wide variety of mammalian cells. Foreign genes were efficiently expressed under the control of the T7 promoter in these cells. The T7 RNA polymerase per se has no capping activity and is localized in the cytoplasm. Therefore, RNA synthesized by this system should be uncapped and present in the cytoplasm. Consequently, an IRES is required for gene expression in this system. This is in contrast to the VacT7 system in which a portion of the RNA transcript was modified by the virus-coded capping enzyme (Elroy-Stein et al., 1989) . Conversely, the T7-adenovirus system may actually provide an advantage for generation of infectious RNA in vivo because of its lack of capping activity. Infectious cDNA clones have been successfully made for flaviviruses (Rice et al., 1989; Lai et al., 1991; Gristun and Gould, 1995; Sumiyoshi et al., 1992) . Authenticity of the sequence at the 5Ј end of the transcripts was shown to be crucial for construction of infectious cDNA clones of these RNA viruses (Boyer and Haenni, 1994) . Inappropriate capping at the 5Ј end by vectors may thus hinder the authentic structure of the RNA and prevent its infectivity.
Many full-length cDNA clones of HCV have been obtained since the first report of cloning and characterization of the prototype HCV cDNA Inchauspe et al., 1991; Kato et al., 1990; Okamoto et al., 1991; Tanaka et al., 1996) . In most cases, the starting materials were plasma pools of blood containing infectious HCV. The cDNA fragments were obtained by RT±PCR by using many sets of primers derived from the prototype HCV sequence. Therefore, it is not certain whether the obtained sequences originated from a single genome of an infectious virion of HCV. There is no sufficient system yet to evaluate the replication of HCV in vitro or to isolate an infectious particle from the quasispecies population of HCV. Therefore, it is impossible to assess the authenticity of the cDNA clones of HCV at present. Recently, it was demonstrated that a full-length HCV RNA transcribed from a consensus cDNA clone of HCV was infectious for a chimpanzee by direct injection into his liver. However, propagation of infectious RNA in cell culture has not been reported so far (Kolykhalov et al., 1997; Yanagi et al., 1997) . In the case of an infectious cDNA clone of classical swine fever virus, only five amino-acid changes abrogated its infectivity (Moormann et al., 1996) .
Instead of full-length clones, establishment of a minigene of HCV may circumvent this difficulty. A modified T7 promoter in pT7HCVLuc was engineered to generate the authentic HCV 5Ј end sequence of the transcript by deleting two Gs. Although deletion of two guanine residues in the transcription initiation site of the promoter decreases the efficiency of transcription in comparison with the authentic one (Milligan et al., 1987) , the expression of luciferase in FLC4 cells was significantly higher than in other cell lines examined. RNA possessing the 5ЈUTR sequence of EMCV is efficiently translated via direct entry of the ribosome at a landing site within the UTR (Bienkowska-Szewczyk and Ehrenfeld, 1988; Trono et al., 1988; Jan et al., 1989; Pelletier and Sonenberg, 1989) Although only a faint signal of transcript from pT7HCVLuc was detected in FLC4 cells (Fig. 4) , the level of luciferase activity in this cells transfected with pT7HCVLuc was comparable to in those transfected with pT7EMCVLuc (Fig. 5) . Therefore, we would have expected the translational efficiency of the RNA possessing HCV 5ЈUTR in FLC4 cells to be enhanced or stabilized. The level of expression of luciferase observed in FLC4 cells transfected with the HCV minigene RNA was only two-to threefold higher than in those transfected with RNA carrying the IRES sequence of EMCV (Fig. 6) . These results 1 and 4) , 48 h (lane 2), and 72 h (lane 3) after transfection. As a positive control HCV core proteins expressed in insect cells by a recombinant baculovirus, Ac39 (Suzuki et al., 1995) , was used (lane 5). The expressed core protein was detected by Western blot analysis. M is a molecular weight marker.
suggest the presence of some host factor(s) which increase the efficiency of translation of the HCV minigene RNA in FLC4 cells. Identification of such host factor(s) and elucidation of the mechanism of the enhancement of translation of the HCV minigene RNA in this cell line are now in progress.
We designed the pT7HCVLuc construct so that the ribozyme sequence of hepatitis D virus may cleave synthesized RNA immediately after the terminal poly (U) sequence. However, the presence of an additional 98 nt of HCV sequence downstream of 3Ј poly (U) tract was recently reported (Kolykhalov et al., 1997; Tanaka et al., 1996) . We also detected the additional 98-nt sequence in both positive and negative strands of HCV RNA (Aizaki et al., 1998) . The effect of the 3Ј terminal sequence on transcriptional or translational efficiency in this system must be determined. So far, however, no difference in reporter gene expression was observed by the addition of the 98-nt extra sequence in the 3Ј end of the pT7HCVLuc in this system (data not shown). Studies of replication of the HCV minigene RNA by supplementing HCV nonstructural proteins with infection with adenovirus vectors are also in progress. The in vivo system used to synthesize the HCV minigene described in this study could offer an efficient tool for studies not only of HCV replication but also of other viruses for which there are no efficient in vitro replication systems.
MATERIALS AND METHODS
Cells
Cells were maintained in Dulbecco's modified Eagle's medium (GIBCO Laboratories, Grand Island, NY) containing 2 mM L-glutamine, penicillin (50 IU/ml), streptomycin (50 g/ml) and supplemented with 10% fetal calf serum. Human hepatocellular carcinoma cell lines (HepG2 and Huh7) were obtained from the American Type Culture Collection and the Japanese Cancer Research Resources Bank (JCRB)-Cell, Tokyo, respectively. A porcine kidney cell line (CPK) (Komaniwa et al., 1981) was kindly provided by Dr. A. Fukusho, National Institute of Animal Health, Tokyo, Japan. The FLC4 cell lines was established by cloning JHH-4 cells (Sujino et al., 1986) , and possesses normal liver functions. The 293 cell line (Graham et al., 1977) was used for propagation and titration of recombinant adenoviruses.
Construction of a recombinant adenovirus
The bacteriophage T7 RNA polymerase gene was excised from pVR-T7±1 (kindly provided by Dr. M. Kohara) with SmaI and EcoRI, filled with the Klenow enzyme and cloned into the SwaI site of transfer cosmid pAxCAwt (Kanegae et al., 1995) . The resultant cosmid was designated pAdexCAT7. The pAxCAwt is a cassette cosmid containing the CAG promoter and an almost full length adenovirus type 5 genome with deletions in the E1 (nt 453±3328) and E3 (nt 28592±30474) regions. The CAG promoter (Niwa et al., 1991) , is a composite promoter consisting to the cytomegalovirus IE enhancer, the chicken ␤-actin promoter and the rabbit ␤-globin polyadenylation [poly(A)] signal. Recombinant adenovirus containing the bacteriophage T7 RNA polymerase, AdexCAT7, was constructed (Fig. 1) as described previously (Miyake et al., 1996) . Briefly, 293 cells were transfected with pAdexCAT7 together with the DNA-terminal protein complex of a parent virus by the calcium phosphate precipitation method (Sambrook et al., 1989) . Recombinant virus was plaque-isolated 10 days after transfection. Viral DNA was extracted together with cellular DNA, and the desired recombinant was identified by restriction analysis (Sambrook et al., 1989) . The AxCAwt virus (Kanegae et al., 1995) , which did not carry an expression unit, was used as a control virus. The recombinant viruses were extensively purified by banding twice through CsCl density gradients and dialyzed against buffer containing 10 mM Tris±HCl (pH 7.5), 10 mM MgCl 2 , and 10% glycerol.
Construction of plasmids
The HCV cDNAs (genotype 1b) used in this study were originally isolated from a blood sample of an HCV carrier, which was infectious for both humans and chimpanzees (NIHJ1 clone) (Aizaki et al., 1998) .
To synthesize HCV minigene RNA, pT7HCVLuc (Fig. 3 ) was constructed as follows: first, to make pUCT707 containing a modified T7 promoter, the HCV 5ЈUTR and part of the core region, the clone pUCAB [containing 1±707 nt (Aizaki et al., 1998) ] was modified by the PCR by using 5Ј primer, 5Ј-AAGCTTAATACGACTCACTAATAGCCAGCCC-CCGATTGGGGGCGACACTCCAT-3Ј, which contains a HindIII site and the modified T7 promoter sequence fused directly to the 5Ј end of the HCV sequence (underlined), and 3Ј primer, 5Ј-TTGTGATGAGCCGATCGTCA-3Ј. To generate pUCT7, 5ЈUTRLuc containing the modified T7 promoter, the 5ЈUTR and the firefly luciferase gene, pUCT707 was digested with ClaI, filled with Klenow, and ligated with an 8-mer BamHI linker (5Ј-CGGATCCG-3Ј). After BamHI and HindII digestion, the fragment was cloned into the HindIII-BamHI site of the PicaGene vector (Toyo Ink, Tokyo, Japan) just upstream of the luciferase gene. To remove the redundant sequences between the 5ЈUTR of HCV and the luciferase gene, the AccI-KasI fragment of the plasmid was replaced with a DNA fragment synthesized by two oligonucleotides, 5Ј-TAGACC-GTGCATCATGGAAGACGCCAAAAACATAAAGAAAGGC-CCGGCGCCATTC-3Ј (top strand) and 5Ј-GAATGGCGCC-GGGCCTTTCTTTATGTTTTTGGCGTCTTCCATGATGCAC-GGTCTA-3Ј (bottom strand), which contains an AccI site (327 nt of HCV) at the 5Ј end and a KasI site (30 nt of the luciferase gene) at the 3Ј end. Thus the initiator AUG of the luciferase gene in pUCT7 5ЈUTRLuc was located 342 nt downstream from the transcription initiation site which is identical to the coding sequence of the HCV core protein. To modify the 3Ј end of pUCT7 5ЈUTRLuc, the BspMI-HindIII fragment (nt 9354±9425) of pUCJK (Aizaki et al., 1998) was replaced with a PCR fragment obtained by using a set of primers, 5Ј-GCGTCCCAGCTGGACTT-GTC-3Ј and 5Ј-TTCGAAATTTTTTTTTTTTTTTCCCCTACC-GGATAACCGGACC-3Ј, which contained 15 nt of poly (U) stretch upstream of the DraI site. The cDNA of the modified pUCJK was digested with Asp718, filled with Klenow enzyme and ligated with an 8-mer XhoI linker (5Ј-CCTC-GAGG-3Ј). The two fragments, the HindIII-XhoI fragment of pUCT7 5ЈUTRLuc and the XhoI-DraI fragment of modified pUCJK, were cloned between the HindIII-SmaI sites of pX8dT (kindly provided by Dr. K. Conzelmann), which is a derivative of pBluescriptII SK(Ϫ) (Stratagene, La Jolla, CA), and the resultant plasmid was designated as pT7HCVLuc. pT7HCVLuc therefore contained the modified T7 promoter, the HCV 5ЈUTR (341 nt), the luciferase gene, a part of NS5B, the HCV 3ЈUTR, a poly (T 15 ) sequence, a hepatitis D virus ribozyme sequence (rHDV), and a T7 promoter termination sequence (T7ter). Transcription of pT7HCVLuc by T7 polymerase was considered to be initiated from the G residue identical to the first nucleotide of the 5Ј end of the HCV and would be terminated after poly (U 15 ) tailing by self-cleavage activity of rHDV.
As a positive control, pT7EMCVLuc was constructed (Fig. 3) . This plasmid was constructed by replacing the T7 promoter and 5ЈUTR of the pT7HCVLuc with the authentic T7 promoter and the 5ЈUTR of EMCV derived from pTM3 (kindly provided by Dr. B. Moss). As a negative control, pT7Luc was constructed by deleting the HCV 5ЈUTR derived from pT7HCVLuc and by replacing the modified T7 promoter with the authentic one (Fig. 3) .
To express HCV core protein using the T7-adenovirus system, pT7HCVcore was constructed (Fig. 3) . This plasmid contains the modified T7 promoter, the HCV 5ЈUTR, the HCV core region, a part of NS5B, the HCV 3ЈUTR, the poly (T 15 ) sequence, rHDV, and T7ter. To normalize the transfection efficiency, pT7EMCVRLuc was constructed and used as an internal control plasmid. Renilla luciferase gene was excised from pRL-null (Promega, Madison, WI) and inserted into the NcoI site of pTM3 under the authentic T7 promoter and the 5ЈUTR of EMCV.
T7 RNA polymerase assay
Two ϫ 10 5 cells in a 12-well plate were infected with AdexCAT7 at m.o.i.'s of 4, 20, and 100. After 48 h, the cells were washed three times with phosphate-buffered saline (PBS), resuspended in 200 l of PBS and sonicated for 5 min at 30-s intervals. After centrifugation, the cell lysates were used for in vitro polymerase as follows: a total of 20 l of a reaction solution containing 1 g of DNA template (pT7Luc , Fig 3) , 2 l of lysate, 2 l of transcription buffer (MEGAscript kit, Ambion, Austin, TX), and 0.15 mM each of ATP, CTP, GTP, UTP, and labeled [ 3 H]UTP (37 KBq) (Daiichi Kagaku, Tokyo) was incubated at 37°C. Fifty units of enzyme mix containing purified T7 RNA polymerase (Promega) and 2 l of lysates of uninfected cells was used as positive and negative controls, respectively. After 3 h of incubation, 8 l of the reaction solution was spotted onto a filtermat (Wallac, Turku, Finland) and dried completely in an 80°C oven, then washed three times with 2ϫ standard saline citrate (0.3 M sodium chloride and 0.03 M sodium citrate) and twice with 95% ethanol. After drying, a Meltilex (Wallac) sheet was laid directly on the dried filtermat and melted at 80°C for 5 min. Subsequently the filtermat with meltilex was removed from the oven, solidified at room temperature and finally placed in a microbeta counter (1450 Microbeta Plus, Wallac) for determination of radioactivity.
Expression of luciferase in cells infected with AdexCAT7
Two ϫ 10 5 cells of various cell lines in a 12-well plate were infected with AdexCAT7 at an m.o.i. of 20. The inocula were removed after 60 min of incubation and replaced with 1 ml of fresh medium. After 24 h of incubation, the medium was removed, the cells were washed twice and the medium was replaced with 500 l of Opti-MEM-medium (GIBCO BRL, Life Technologies, Gaithersburg, MD). Reporter plasmid containing firefly luciferase gene (1 g), pT7EMCVRLuc containing Renilla luciferase gene as an internal control plasmid (0.1 g) and lipofectin (GIBCO BRL) (2.5 l) were mixed with 50 l of Opti-MEM and the infected cells were transfected with the mixture after 15 min of incubation. The cells were examined for expression of reporter genes at 24 h after transfection. Firefly and Renilla luciferase activities were determined by the dual-luciferase reporter assay system (Promega) following the manufacture's instructions. Briefly, cells were washed twice with PBS and lysed with passive lysis buffer (Promega). After centrifugation, the cell lysates were used for the assay of two luciferase reporter enzymes. Since the firefly and Renilla luciferases have dissimilar enzyme structures and substrate requirements, it is possible to selectively discriminate between their respective bioluminescent reactions. The firefly luciferase reporter assay was initiated by adding the cell lysates to luciferase assay buffer (Promega). Then to quench of firefly luciferase luminescence and simultaneously activate the luminescent reaction of Renilla luciferase, Stop and Glo Buffer (Promega) was added to the same tube. Relative light units (RLU) were measured with a luminometer (Berthold, Wildbad, Germany), and firefly luciferase activity was normalized with that of Renilla luciferase. Total protein was quantified by using BCA protein assay reagents (Pierce Chemical Co., Rockford, IL).
Northern blot analysis
Total RNA was prepared from cells infected with AdexCAT7 and then transfected with the reporter plasmids by RNA zol B (Cinna/Biotecx, Friendswood, TX). RNA was denatured at 65°C for 15 min in 5.8 l of sample buffer (17.5% formaldehyde and 50% formamide in 1ϫ MOPS buffer, 20 mM MOPS, 5 mM sodium acetate, and 1 mM EDTA pH 7.0). After cooling in ice-cold water, the RNA in 7.5 l of 2ϫ loading buffer (80% formamide, 0.1% bromphenol blue, 0.1% xylene cyanol, 2 mM EDTA) was separated on a formaldehyde-denatured agarose gel (18% formaldehyde, 1% agarose) in 1ϫ MOPS buffer. The gel was washed twice with 20ϫ SSC (3 M NaCl, 0.3 M trisodium citrate dihydrate, pH 7.0) for 15 min and transferred onto a Hybond N ϩ membrane filter (Amersham Life Science, Buckinghamshire, England) by the capillary method. The filter was dried and RNAs were fixed on the membrane with UV light (UV Crosslinker, Funakoshi, Tokyo). The RNA was randomly labeled with digoxigenin (DIG)-UTP in vitro using the luciferase gene as a template. Luciferase-specific RNA was detected with a DIG luminescent detection kit (Boehringer GmbH, Mannheim, Germany) according to the manufacturer's protocol.
The nucleotide sequences of the 5Ј and 3Ј UTRs of the HCV minigene RNA using AdexCAT7
Total RNA was extracted from cells infected with AdexCAT7 and then transfected with pT7HCVLuc as described above. The nucleotide sequence of the 5Ј terminus position was determined after amplification of the 5Ј terminus region using the 5Ј RACE for rapid amplification of cDNA ends kit (GIBCO BRL). Briefly, first strand cDNA was synthesized from total RNA using a 20-mer primer, Aa1 (5Ј)-GTTGATCCAAGAAAGGACCC-3Ј) (Aizaki et al., 1998) using reverse transcriptase (Takara Shuzo, Kyoto). A homopolymeric tail, using dCTP and terminal deoxyl terminal transferase, was then added to the 3Ј end of cDNA. The 5Ј terminus sequence (position 1 to 207) was determined by PCR-based sequencing using the M13RV (5Ј-CAGGAAACAGCTATGAC-3Ј) and J36A primers.
The nucleotide sequence of the 3Ј terminus position was determined by the oligo RNA ligation method (Tanaka et al., 1996) . Briefly, the 5Ј-phosphorylated oligo RNA (5Ј-CCC-GUCUUCGGACAUCCAGAGGUAU-3Ј) was synthesized (Takara Shuzo) and ligated to RNA by T4 RNA ligase (Takara Shuzo) at 10°C for 15 h and then reverse transcribed with primer La1 (5Ј-CCATCCTAATACGACTCAC-TATAGGGC-3Ј) at 50°C for 1 h. The reverse transcript was amplified by nested PCR (94°C for 1 min, 55°C for 1 min, 72°C for 2 min, 40 cycles) with sets of the primers (1st PCR: Ks1; 5Ј-TACTCCTACTCTCTGTAGGG-3Ј and La1; 2nd PCR: Ks2; 5Ј-GGCATCTACCTGCTCCCCAA-3Ј and La2; 5Ј-ACTCACTATAGGGCTCGAGCGGC-3Ј). The 3Ј terminus sequences were determined by PCR-based sequencing
In vitro transcription
RNAs were synthesized with a MEGAscript kit according to the manufacturer's instruction. Briefly, the transcription reaction was carried out at 37°C for 2 h in a total 20 l reaction solution containing 1 g of DNA template, 2 l of 10ϫ transcription buffer, 2 l of enzyme mix, 2 l of 10ϫ transcription buffer, 2 l each of 75 mM ATP, CTP, GTP, and UTP. The mixture was treated twice with 8 units of DNase at 37°C for 20 min and precipitated with ethanol. After being washed with 75% ethanol, the precipitate was dissolved in water.
RNA transfection
Cells (2 ϫ 10 5 ) in a 12-well plate were washed twice with 500 l of Opti-MEM (GIBCO BRL) medium and replaced with the same volume of Opti-MEM medium. In vitro-synthesized RNA (2 g) and lipofectin (GIBCO BRL) (2.5 l) were mixed with 50 l of Opti-MEM, and cells were transfected with the mixture after 15 min of incubation. To normalize the transfection efficiency, RNA synthesized from pT7EMCVRLuc was used as an internal control. At 6 h after transfection, the cells were harvested for luciferase assay as described above.
Western blot
Cell extracts were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis, and proteins were blotted onto a polyvinylidene difluoride membrane (Millipore, Tokyo). Anti-T7 polymerase rabbit polyclonal antibody (kindly provided by Dr. F. W. Studdier) and a mouse monoclonal antibody raised against the core protein of HCV (Suzuki et al., 1995) were used as the first antibody. The expressed proteins were detected with an alkaline phosphatase assay kit (Bio-Rad Laboratories, Hercules, CA).
